Eversept Partners LP Makes New Investment in CVS Health Corporation $CVS

Eversept Partners LP bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the 4th quarter, HoldingsChannel.com reports. The fund bought 63,696 shares of the pharmacy operator’s stock, valued at approximately $5,055,000.

Other hedge funds have also recently modified their holdings of the company. Swiss RE Ltd. bought a new position in shares of CVS Health during the 4th quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd increased its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Ares Financial Consulting LLC bought a new stake in shares of CVS Health in the 4th quarter worth approximately $29,000. Dogwood Wealth Management LLC raised its holdings in shares of CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 179 shares during the period. Finally, GoalVest Advisory LLC bought a new stake in shares of CVS Health in the 4th quarter worth approximately $32,000. Institutional investors own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CVS. Wall Street Zen cut shares of CVS Health from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. HSBC lifted their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Tuesday, May 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Finally, Sanford C. Bernstein lifted their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Stock Down 1.6%

CVS Health stock opened at $99.06 on Thursday. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $102.77. The firm has a market capitalization of $126.40 billion, a price-to-earnings ratio of 43.64, a P/E/G ratio of 0.99 and a beta of 0.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm has a 50 day simple moving average of $88.51 and a 200 day simple moving average of $81.24.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the business earned $2.25 EPS. CVS Health’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. 0.85% of the stock is owned by company insiders.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.